oalib

Publish in OALib Journal

ISSN: 2333-9721

APC: Only $99

Submit

Any time

2019 ( 13 )

2018 ( 19 )

2017 ( 26 )

2016 ( 38 )

Custom range...

Search Results: 1 - 10 of 8692 matches for " Elizabeth Tocci "
All listed articles are free for downloading (OA Articles)
Page 1 /8692
Display every page Item
Low Dose Total Skin Electron Beam Radiation in Cutaneous T-Cell Lymphoma: Review  [PDF]
Misty Gamble, Elizabeth Tocci, Jennifer A. DeSimone
Journal of Cancer Therapy (JCT) , 2014, DOI: 10.4236/jct.2014.514138
Abstract: The treatment of advanced stage MF is especially challenging as single agent overall response rates are in the 35% range and chronic recurrence is the rule. The treatment of CTCL across all stages of disease is aimed at the goal of achieving and sustaining remission. Increasingly, low dose total skin electron beam therapy (TSEBT) is being utilized as a skin directed component in combination therapy for advanced stage CTCL. Researchers are seeking to better define the utility of low dose TSEBT as a method of debulking skin disease while simultaneously treating other disease compartments and in combination with sustained maintenance therapies of both the skin directed and systemic varieties. Data exists showing the efficacy of low dose TSEBT in early and advanced disease. There is also data documenting prolonged treatment responses with TSEBT plus adjuvant skin directed therapies such as PUVA and topical nitrogen mustard. Emerging data examining the role of low dose TSEBT in the prestem cell transplant preparation is also promising. This brief review summarizes the utility of low dose TSEBT in multiagent treatment regimens in CTCL.
Kopist vs. Verfasser: Zur Interpunktion im Codex Vatic. gr. 1889 (13. Jh.)
Raimondo Tocci
Parekbolai : an Electronic Journal for Byzantine Literature , 2011,
Abstract: Ziel der Untersuchung ist es, am Beispiel des Codex Vaticanus gr. 1889 die Interpunktionsgewohnheiten des Autor-Kopisten Theodoros Skutariotes herauszuarbeiten und somit einen Beitrag zum n heren Verst ndnis der Stixis in mittelalterlichen Handschriften zu leisten. Die Interpunktion der im Vaticanus autograph überlieferten Χρονικ wird jener der von Theodoros in dieser Handschrift kopierten Texte gegenübergestellt, und die Funktionen der einzelnen Zeichen vergleichend diskutiert. Auf der Basis der gewonnenen Ergebnisse wird die übertragbarkeit der mittelalterlichen Interpunktion auf die moderne Editionspraxis er rtert.
Olmesartan medoxomil for the treatment of hypertension in children and adolescents
Tocci G, Volpe M
Vascular Health and Risk Management , 2011, DOI: http://dx.doi.org/10.2147/VHRM.S11672
Abstract: artan medoxomil for the treatment of hypertension in children and adolescents Review (4465) Total Article Views Authors: Tocci G, Volpe M Published Date March 2011 Volume 2011:7 Pages 177 - 181 DOI: http://dx.doi.org/10.2147/VHRM.S11672 Giuliano Tocci1, Massimo Volpe1,2 1Chair and Division of Cardiology, Department of Clinical and Molecular Medicine, Faculty of Medicine, University of Rome “Sapienza”, Sant’Andrea Hospital, Rome; 2IRCCS Neuromed, Pozzilli, Italy Abstract: Prevalence of hypertension in children and adolescents has progressively and continuously increased over recent decades. Thus, early and effective control of high blood pressure may be considered an effective therapeutic approach, in order to reduce the burden of hypertension-related cardiovascular disease in future. In the past, due to the absence of prospective, long-term, randomized, controlled clinical trials performed in young hypertensive patients, lifestyle changes have been long seen as the only strategy to reduce high blood pressure levels. More recently, clinical data on the efficacy and safety of five major classes of antihypertensive drugs (including angiotensin converting enzyme inhibitors, angiotensin receptor blockers [ARBs], beta-blockers, calcium-antagonists, and diuretics) have become available. In particular, these trials demonstrated dose-dependent blood pressure reductions and a good tolerability profile of several ARBs in hypertensive children and adolescents. An overview is provided of the clinical benefits of early detection and prompt intervention of high blood pressure levels, with a closer analysis of recent clinical trials, performed with olmesartan medoxomil in young subjects with hypertension.
Rationale for triple fixed-dose combination therapy with an angiotensin II receptor blocker, a calcium channel blocker, and a thiazide diuretic
Volpe M, Tocci G
Vascular Health and Risk Management , 2012, DOI: http://dx.doi.org/10.2147/VHRM.S28359
Abstract: tionale for triple fixed-dose combination therapy with an angiotensin II receptor blocker, a calcium channel blocker, and a thiazide diuretic Original Research (2712) Total Article Views Authors: Volpe M, Tocci G Published Date June 2012 Volume 2012:8 Pages 371 - 380 DOI: http://dx.doi.org/10.2147/VHRM.S28359 Received: 18 November 2011 Accepted: 23 December 2011 Published: 11 June 2012 Massimo Volpe,1,2 Giuliano Tocci2 1Division of Cardiology, Department of Clinical and Molecular Medicine, University of Rome, Sapienza, Sant'Andrea Hospital, Rome, 2IRCCS Neuromed, Pozzilli, Italy Abstract: Hypertension is a growing global health problem, and is predicted to affect 1.56 billion people by 2025. Treatment remains suboptimal, with control of blood pressure achieved in only 20%–35% of patients, and the majority requiring two or more antihypertensive drugs to achieve recommended blood pressure goals. To improve blood pressure control, the European hypertension guidelines recommend that angiotensin II receptor blockers (ARBs) or angiotensin-converting enzyme inhibitors (ACEIs) are combined with calcium channel blockers (CCBs) and/or thiazide diuretics. The rationale for this strategy is based, in part, on their different effects on the renin-angiotensin system, which improves antihypertensive efficacy. Data from a large number of trials support the efficacy of ACEIs or ARBs in combination with CCBs and/or hydrochlorothiazide (HCTZ). Combining two different classes of antihypertensive drugs has an additive effect on lowering of blood pressure, and does not increase adverse events, with the ARBs showing a tolerability advantage over the ACEIs. Among the different ARBs, olmesartan medoxomil is available as a dual fixed-dose combination with either amlodipine or HCTZ, and the increased blood pressure-lowering efficacy of these two combinations is proven. Triple therapy is required in 15%–20% of treated uncontrolled hypertensive patients, with a renin-angiotensin system blocker, CCB, and thiazide diuretic considered to be a rational combination according to the European guidelines. Olmesartan, amlodipine, and HCTZ are available as a triple fixed-dose combination, and significant blood pressure reductions have been observed with this regimen compared with the possible dual combinations. The availability of these fixed-dose combinations should lead to improvement in blood pressure control and aid compliance with long-term therapy, optimizing the management of this chronic condition.
Cyprus / Chapter 2 of Europeanization and Conflict Resolution: Case Studies from the European Periphery
Nathalie Tocci,Tamara Kovziridze
Journal on Ethnopolitics and Minority Issues in Europe , 2004,
Abstract: This chapter reviews the impact of Europeanization on the Cyprus conflict. Since 1974, the UN has developed increasingly detailed proposals for a bi-zonal, bi-communal federation. But throughout the decades of failed negotiations the main parties have essentially stuck to their negotiating positions. In the 1990s, with Cyprus' application for EU membership, the EU became a key external determinant of the evolution of the conflict. Indeed, because of Cyprus' accession process and Turkey's own aspirations to join the Union, the parties to the conflict equate Europeanization with EU-ization. EU-ization in Cyprus has two dimensions: the impact of the EU as a framework on conflict resolution efforts, and the impact of the accession process on the parties in conflict. The latter dimension of Europeanization has had both intended and unintended effects, which in turn are likely to impinge on future developments in the eastern Mediterranean.
Olmesartan medoxomil for the treatment of hypertension in children and adolescents
Tocci G,Volpe M
Vascular Health and Risk Management , 2011,
Abstract: Giuliano Tocci1, Massimo Volpe1,21Chair and Division of Cardiology, Department of Clinical and Molecular Medicine, Faculty of Medicine, University of Rome “Sapienza”, Sant’Andrea Hospital, Rome; 2IRCCS Neuromed, Pozzilli, ItalyAbstract: Prevalence of hypertension in children and adolescents has progressively and continuously increased over recent decades. Thus, early and effective control of high blood pressure may be considered an effective therapeutic approach, in order to reduce the burden of hypertension-related cardiovascular disease in future. In the past, due to the absence of prospective, long-term, randomized, controlled clinical trials performed in young hypertensive patients, lifestyle changes have been long seen as the only strategy to reduce high blood pressure levels. More recently, clinical data on the efficacy and safety of five major classes of antihypertensive drugs (including angiotensin converting enzyme inhibitors, angiotensin receptor blockers [ARBs], beta-blockers, calcium-antagonists, and diuretics) have become available. In particular, these trials demonstrated dose-dependent blood pressure reductions and a good tolerability profile of several ARBs in hypertensive children and adolescents. An overview is provided of the clinical benefits of early detection and prompt intervention of high blood pressure levels, with a closer analysis of recent clinical trials, performed with olmesartan medoxomil in young subjects with hypertension.Keywords: hypertension, high blood pressure, children, adolescents, antihypertensive treatment, olmesartan medoxomil
Rationale for triple fixed-dose combination therapy with an angiotensin II receptor blocker, a calcium channel blocker, and a thiazide diuretic
Volpe M,Tocci G
Vascular Health and Risk Management , 2012,
Abstract: Massimo Volpe,1,2 Giuliano Tocci21Division of Cardiology, Department of Clinical and Molecular Medicine, University of Rome, Sapienza, Sant'Andrea Hospital, Rome, 2IRCCS Neuromed, Pozzilli, ItalyAbstract: Hypertension is a growing global health problem, and is predicted to affect 1.56 billion people by 2025. Treatment remains suboptimal, with control of blood pressure achieved in only 20%–35% of patients, and the majority requiring two or more antihypertensive drugs to achieve recommended blood pressure goals. To improve blood pressure control, the European hypertension guidelines recommend that angiotensin II receptor blockers (ARBs) or angiotensin-converting enzyme inhibitors (ACEIs) are combined with calcium channel blockers (CCBs) and/or thiazide diuretics. The rationale for this strategy is based, in part, on their different effects on the renin-angiotensin system, which improves antihypertensive efficacy. Data from a large number of trials support the efficacy of ACEIs or ARBs in combination with CCBs and/or hydrochlorothiazide (HCTZ). Combining two different classes of antihypertensive drugs has an additive effect on lowering of blood pressure, and does not increase adverse events, with the ARBs showing a tolerability advantage over the ACEIs. Among the different ARBs, olmesartan medoxomil is available as a dual fixed-dose combination with either amlodipine or HCTZ, and the increased blood pressure-lowering efficacy of these two combinations is proven. Triple therapy is required in 15%–20% of treated uncontrolled hypertensive patients, with a renin-angiotensin system blocker, CCB, and thiazide diuretic considered to be a rational combination according to the European guidelines. Olmesartan, amlodipine, and HCTZ are available as a triple fixed-dose combination, and significant blood pressure reductions have been observed with this regimen compared with the possible dual combinations. The availability of these fixed-dose combinations should lead to improvement in blood pressure control and aid compliance with long-term therapy, optimizing the management of this chronic condition.Keywords: angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, calcium channel blockers, triple therapy, hypertension
Solvent Induced Proton Hopping at a Water-Oxide Interface
Gabriele Tocci,Angelos Michaelides
Physics , 2014, DOI: 10.1021/jz402646c
Abstract: Despite widespread interest, a detailed understanding of the dynamics of proton transfer at interfaces is lacking. Here we use ab initio molecular dynamics to unravel the connection between interfacial water structure and proton transfer for the widely studied and experimentally well-characterized water-ZnO$(10\bar{1}0)$ interface. We find that upon going from a single layer of adsorbed water to a liquid multilayer changes in the structure are accompanied by a dramatic increase in the proton transfer rate at the surface. We show how hydrogen bonding and rather specific hydrogen bond fluctuations at the interface are responsible for the change in the structure and proton transfer dynamics. The implications of this for the chemical reactivity and for the modelling of complex wet oxide interfaces in general are also discussed.
Optimal Antihypertensive Combination Treatments
Massimo Volpe,Giuliano Tocci,Sami A. Omar
European Journal of Cardiovascular Medicine , 2012,
Abstract: Over the past three decades it has been consistently shown that optimal blood pressure (BP) control significantly reduced cardiovascular (CV) morbidity and mortality [1]. Despite solid evidence in favour of benefits derived from BP reductions, however, hypertension control in treated hypertensive patients remains suboptimal worldwide [2, 3]. In addition, proportions of diagnosed and treated hypertensive patients remain largely unchanged over the last two decades[4]. Multiple factors may be advocated to explain this observation, including variation in healthcare access and availability [5, 6], attitudes amongst clinicians towards hypertension [7, 8], inaccuracy in BP measurements [9] and underuse or under dosage of antihypertensive drugs in both monotherapy and in combination therapy [10, 11].On the basis of these considerations, it is beyond the aim of this article to discuss the socioeconomic impact on healthcare and BP measurement techniques. Instead it will seek to explain the importance of attaining early optimal BP control and the use of combination therapy as a new paradigm for the modern clinical management of hypertension.
Friction of Water on Graphene and Hexagonal Boron Nitride from ab initio Methods: Very Different Slippage Despite Very Similar Interface Structures
Gabriele Tocci,Laurent Joly,Angelos Michaelides
Physics , 2015, DOI: 10.1021/nl502837d
Abstract: Friction is one of the main sources of dissipation at liquid water/solid interfaces. Despite recent progress, a detailed understanding of water/solid friction in connection with the structure and energetics of the solid surface is lacking. Here we show for the first time that \textit{ab initio} molecular dynamics can be used to unravel the connection between the structure of nanoscale water and friction for liquid water in contact with graphene and with hexagonal boron nitride. We find that whilst the interface presents a very similar structure between the two sheets, the friction coefficient on boron nitride is $\approx 3$ times larger than that on graphene. This comes about because of the greater corrugation of the energy landscape on boron nitride arising from specific electronic structure effects. We discuss how a subtle dependence of the friction on the atomistic details of a surface, that is not related to its wetting properties, may have a significant impact on the transport of water at the nanoscale, with implications for the development of membranes for desalination and for osmotic power harvesting.
Page 1 /8692
Display every page Item


Home
Copyright © 2008-2017 Open Access Library. All rights reserved.